Literature DB >> 15720143

Ternary complexes of gentamicin with iron and lipid catalyze formation of reactive oxygen species.

Wojciech Lesniak1, Vincent L Pecoraro, Jochen Schacht.   

Abstract

This study was designed to elucidate the mechanisms underlying the formation of reactive oxygen species (ROS) by aminoglycoside antibiotics which may be causally related to the toxic side effects of these drugs to the kidney and the inner ear. ROS formation by aminoglycosides in vitro requires iron and the presence of polyunsaturated lipids as electron donors. Electron spray ionization mass spectrometry (ESI-MS) confirmed earlier observations that gentamicin strongly binds to L-alpha-phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), a membrane lipid rich in arachidonic acid. Studies using lipid-coated membranes (PIP strips) further indicated that iron ions and gentamicin can simultaneously bind to phosphoinositides with at least one phosphate group on the inositol ring, suggesting the existence of ternary complexes among gentamicin, iron, and phospholipids. Peroxidation of PtdIns(4,5)P2 by ferrous ions significantly increased in the presence of gentamicin, and EI-MS measurements indicated that oxidative damage to PtdIns(4,5)P2 was accompanied by the release of arachidonic acid. Arachidonic acid also forms a ternary complex with Fe(2+/3+)-gentamicin, confirmed by ESI-MS, that reacts with lipid peroxides and molecular oxygen, leading to the propagation of arachidonic acid peroxidation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15720143     DOI: 10.1021/tx0496946

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  17 in total

1.  Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment.

Authors:  Hyejeong Hong; Kelly E Dooley; Laura E Starbird; Howard W Francis; Jason E Farley
Journal:  Arch Toxicol       Date:  2019-04-08       Impact factor: 5.153

Review 2.  Intracellular mechanisms of aminoglycoside-induced cytotoxicity.

Authors:  Takatoshi Karasawa; Peter S Steyger
Journal:  Integr Biol (Camb)       Date:  2011-07-29       Impact factor: 2.192

Review 3.  Apoptosis in acquired and genetic hearing impairment: the programmed death of the hair cell.

Authors:  Ken Op de Beeck; Jochen Schacht; Guy Van Camp
Journal:  Hear Res       Date:  2011-07-18       Impact factor: 3.208

4.  Calreticulin binds to gentamicin and reduces drug-induced ototoxicity.

Authors:  Takatoshi Karasawa; Qi Wang; Larry L David; Peter S Steyger
Journal:  Toxicol Sci       Date:  2011-07-23       Impact factor: 4.849

Review 5.  Tissue Culture Models of AKI: From Tubule Cells to Human Kidney Organoids.

Authors:  Julie Bejoy; Eddie S Qian; Lauren E Woodard
Journal:  J Am Soc Nephrol       Date:  2022-01-14       Impact factor: 10.121

6.  Mitochondrial calcium uptake underlies ROS generation during aminoglycoside-induced hair cell death.

Authors:  Robert Esterberg; Tor Linbo; Sarah B Pickett; Patricia Wu; Henry C Ou; Edwin W Rubel; David W Raible
Journal:  J Clin Invest       Date:  2016-08-08       Impact factor: 14.808

7.  Rac/Rho pathway regulates actin depolymerization induced by aminoglycoside antibiotics.

Authors:  Hongyan Jiang; Su-Hua Sha; Jochen Schacht
Journal:  J Neurosci Res       Date:  2006-06       Impact factor: 4.164

8.  Gallium Potentiates the Antibacterial Effect of Gentamicin against Francisella tularensis.

Authors:  Helena Lindgren; Anders Sjöstedt
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

9.  Redox biology of exercise.

Authors:  Michalis G Nikolaidis; Chad M Kerksick; Manfred Lamprecht; Steven R McAnulty
Journal:  Oxid Med Cell Longev       Date:  2012-09-19       Impact factor: 6.543

10.  A mutation in synaptojanin 2 causes progressive hearing loss in the ENU-mutagenised mouse strain Mozart.

Authors:  Shehnaaz S M Manji; Louise H Williams; Kerry A Miller; Lisa M Ooms; Melanie Bahlo; Christina A Mitchell; Hans-Henrik M Dahl
Journal:  PLoS One       Date:  2011-03-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.